(Q35125786)

6 August 2017

title

Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation (English)

1 reference

6 August 2017

0 references

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0041-1345(03)00231-8

1 January 2024

author name string

A. S. MacDonald

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12742497

1 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0041134503002318?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S0041-1345(03)00231-8

https://api.elsevier.com/content/article/PII:S0041134503002318?httpAccept=text/plain

1 January 2024

1 reference

DOI

https://api.crossref.org/works/10.1016/S0041-1345(03)00231-8

Transplantation Proceedings

1 January 2024

published in

1 reference

6 August 2017

volume

35

1 reference

6 August 2017

issue

3 Suppl

1 reference

6 August 2017

page(s)

201S-208S

1 reference

Inhibition of the immune response by rapamycin, a new antifungal antibiotic

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

New antitumor substances of natural origin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Rapamycin for immunosuppression in organ allografting.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Immunopharmacology of rapamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Sirolimus-tacrolimus combination immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Orthotopic liver transplantation using low-dose tacrolimus and sirolimus

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Sirolimus-tacrolimus combination for combined kidney-pancreas transplantation: effect on renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2803%2900231-8

7 January 2021

Identifiers

DOI

1 reference

6 August 2017

1 reference